Download PDF
Onkologische Welt 2017; 08(05): 218-220
DOI: 10.1055/s-0038-1639635
WCGC Barcelona
Schattauer GmbH

Therapieoptimierung bei gastrointestinalen Tumoren

19. World Congress on Gastrointestinal Cancer 2017
Ine Schmale Dr.
Further Information

Publication History

Publication Date:
10 March 2018 (online)

Also available at
    Permissions and Reprints

Für eine verbesserte Behandlung von Patienten mit gastrointestinalen Tumoren sind nicht immer neue Therapien notwendig. Manchmal bringt schon die richtige Einschätzung der Lebensqualität Hinweise auf einen Progress oder die Lage des Primärtumors hat einen Einfluss auf Therapiestrategien, wo kein Einfluss erwartet wurde. Lesen Sie im Folgenden mehr über Neuigkeiten zu gastrointestinalen Tumoren, die beim WCGC in Barcelona präsentiert wurden.

 

  • Literatur

  • 1 Chau I. et al. Associations of quality of life with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD. WCGC 2017. Abstract O-016
    Google Scholar
  • 2 Wilke H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A doubleblind, randomised phase 3 trial. Lancet Oncology 2014; 15: 1224-1235.
    CrossrefPubMedGoogle Scholar
  • 3 Fuchs CS. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39.
    CrossrefPubMedGoogle Scholar
  • 4 Modest DP. et al. Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (Ml22011)-study. WCGC. 2017 Abstract O-026
    PubMedGoogle Scholar
  • 5 van Hazel G. et al. Impact of primary tumour location on survival benefit in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as firstline therapy. WCGC. 2017 Abstract LBA-006
    PubMedGoogle Scholar
  • 6 van Cutsem E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506.
    CrossrefPubMedGoogle Scholar
  • 7 van Cutsem E. et al. Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial. WCGC. 2017 Abstract O-012
    PubMedGoogle Scholar